High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL Meeting Abstract
| Authors: | Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; Jackson, C.; Shukla, N.; Spitzer, B.; Prockop, S.; Steinherz, P. G.; Kung, A. L.; O'Reilly, R. J.; Riviere, I.; Sadelain, M.; Brentjens, R. J. |
| Abstract Title: | High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419403150 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1326.1326 |
| Notes: | Meeting Abstract: 1326 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
